Rising Adoption Of Non-Invasive Screening Techniques Is Anticipated To Open Up New Avenues For The Leukemia Screening Market
The leukemia screening market The leukemia screening market is estimated to be valued at US$ 17.04 Bn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview : Leukemia screening refers to diagnostic tests used to detect presence of leukemia in blood or bone marrow. Leukemia is a type of cancer affecting the blood and bone marrow. The key products used in leukemia screening include next-generation sequencing tests, ELISA tests, immunohistochemistry, molecular diagnostic tests, and flow cytometry. These tests help detect specific leukemia cells and classify the disease subtype. They play a vital role in disease diagnosis and treatment planning. Market Dynamics : Rising prevalence of leukemia across the globe is a key factor driving the market growth. According to data by WHO, leukemia accounted for 3.5% of total cancer cases and 2.8% of cancer deaths worldwide